Welcome!
Hyphens Pharma International
Results
Hyphens Pharma reports 49.7% higher 1QFY2022 NPAT of $3.2 mil
Revenue increased by 18.5% y-o-y to $39.2 million thanks to contributions from its three business segments and Novem.
May 13, 2022
Results
Hyphens Pharma reports better 2HFY2021 earnings, proposes higher dividend
The company plans to pay a first and final dividend of 0.67 cents, slightly improved from 0.62 cents paid for FY2020.
February 23, 2022
Broker's Calls
Brokers' Digest: Econ Healthcare, IHH Healthcare, UOB, Food Empire, Netlink NBN Trust, Hyphens Pharma
See the analysts' recommendations and target prices here.
January 13, 2022
Contracts
Hyphens Pharma signs exclusive licensing deal of Ustekinumab biosimilar for Singapore, Malaysia and the Philippines
The exclusive license and supply agreement will not have a material effect on the group’s NTA or EPS for FY2021.
December 14, 2021
Broker's Calls
Hyphens Pharma 9M21 PATMI exceeds expectations amidst speed bump in Vietnam: PhillipCapital
For the 9MFY2021 ended September, Hyphens Pharma reported PATMI of $1.09 million, 28.8% higher y-o-y
November 25, 2021
M&A
Hyphens Pharma acquires Novem group of companies for $16.3 mil
The acquisition will be earnings accretive for Hyphens Pharma.
November 09, 2021
Medtech
Hyphens Pharma awarded e-pharmacy licence for WellAway Pharmacy
Shares in Hyphens Pharma closed 1 cent higher or 3.2% up at 32.5 cents on Jan 7.
January 07, 2021
Broker's Calls
960 Brokers' Digest
Take a look at these six stocks this week, including Silverlake, Genting Singapore and Hyphens Pharma.
November 20, 2020
Broker's Calls
959 Brokers' Digest
Take a look at these six stocks this week, including Starburst Holdings, Netllink NBN Trust and StarHub.
November 13, 2020
Broker's Calls
KGI gives Hyphens a ‘buy', saying 'skin is the game'
KGI is initiating coverage on Hyphens Pharma with an “outperform” call and a target price of 48 cents.
November 10, 2020